Changes in cellular proliferation and plasma products are associated with liver failure

doi:10.4254/wjh.v8.i32.1370

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7760)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

457

WORD

253

HTML

3173

Figures (1-4)

231

Tables (1-6)

214

Sum=4328

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1050

Download

2382

Sum=3432

Nov 18, 2016 (publication date) through Aug 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Hepatol. Nov 18, 2016; 8(32): 1370-1383
Published online Nov 18, 2016. doi: 10.4254/wjh.v8.i32.1370

Table 6 Variables from mitogen-stimulated peripheral blood mononuclear cells from non-viral acute hepatitis patients and healthy control subjects

Phenotypes/cytokines (PHA/LPS)	HC (n = 10)	AH (n = 8)	ALF (n = 5)	HC vs AH	HC vs ALF	AH vs ALF
PI of CD3⁺	133.1 ± 71.12	173.3 ± 91.84	268.4 ± 101.6	ns	ns	ns
	(95.19-171.0)	(96.51-250.1)	(142.3-394.5)
CD4⁺CD25⁺FoxP3⁺ (%)	17.23 ± 9.74	15.82 ± 8.13	6.84 ± 5.12	ns	ns	ns
	(12.03-22.42)	(9.02-22.62)	(0.48-13.2)
CD4⁺CD29⁺CD44⁺ (%)	38.63 ± 18.37	21.84 ± 7.50	36.67 ± 14.54	ns	ns	ns
	(28.84-48.42)	(15.56-28.11)	(18.61-54.73)
CD8⁺CD29⁺CD44⁺(%)	39.76 ± 19.91	22.26 ± 11.16	29.59 ± 15.21	ns	ns	ns
	(29.15-50.36)	(12.92-31.59)	(10.71-48.47)
CD3^-CD56⁺CD16^- (%)	8.31 ± 6.75	6.33 ± 4.13	17.22 ± 4.94	ns	0.0289	0.0030
	(2.07-14.56)	(2.88-9.79)	(13.09-21.35)
CD3^-CD56^lowCD16⁺ (%)	12.70 ± 8.93	11.38 ± 4.67	27.66 ± 3.49	ns	0.0061	0.007
	(4.44-20.96)	(7.05-15.71)	(22.11-33.21)
CD3⁺CD56⁺CD16⁺ (%)	13.66 ± 3.54	11.63 ± 3.01	8.52 ± 4.97	ns	ns	ns
	(11.77-15.55)	(9.11-14.15)	(2.35-14.70)
IL-6 (pg/mL)	2625.33 ± 3320	966 ± 622.6	1309 ± 851.6	ns	ns	ns
	(856.5-4394)	(445.5-1486.0)	(251.60-2366)
TNFα (pg/mL)	1675.20 ± 623.4	1497 ± 219.8	3217 ± 991.5	ns	0.0044	0.0016
	(1343-2007)	(1313-1681)	(1986-4448)
IL-10 (pg/mL)	528.86 ± 755.1	217.1 ± 159.1	152.1 ± 126.4	ns	ns	ns
	(126.5-931.2)	(84.12-350.2)	(-4.89-309.0)
IFNγ (pg/mL)	3379.1 ± 1869	2257 ± 2872	1378 ± 2533	ns	ns	ns
	(2383-4375)	(-143.3-4658)	(-1767-4524)
IL-8 (pg/mL)	273.9 ± 116.3	293.9 ± 120.2	733.1 ± 404.8	ns	0.0267	ns
	(211.9-335.9)	(193.4-394.4)	(230.4-1236)
IL-17 (pg/mL)	73.81 ± 107.0	36.31 ± 34.62	62.73 ± 5.78	ns	ns	ns
	(16.81-130.8)	(7.36-65.25)	(55.55-69.91)

The differences between the non-viral acute liver failure (ALF) patients, the self-limited acute hepatitis (AH) patients, and the healthy control (HC) subjects were evaluated by intergroup comparisons using the Mann-Whitney U-test. The significance cutoff for all statistical analyses was defined as P < 0.05. IL: Interleukin; IFNγ: Interferon gamma; TNFα: Tumor necrosis factor alpha; PI: Proliferation index; HC: Healthy control; ns: Not significant.

Citation: Melgaço JG, Soriani FM, Sucupira PHF, Pinheiro LA, Vieira YR, de Oliveira JM, Lewis-Ximenez LL, Araújo CCV, Pacheco-Moreira LF, Menezes GB, Cruz OG, Vitral CL, Pinto MA. Changes in cellular proliferation and plasma products are associated with liver failure. World J Hepatol 2016; 8(32): 1370-1383
URL: https://www.wjgnet.com/1948-5182/full/v8/i32/1370.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i32.1370